GW Henssler & Associates Ltd. Boosts Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

GW Henssler & Associates Ltd. boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 201,504 shares of the medical equipment provider’s stock after acquiring an additional 218 shares during the period. GW Henssler & Associates Ltd. owned 0.10% of Zimmer Biomet worth $21,752,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ZBH. Crewe Advisors LLC purchased a new position in shares of Zimmer Biomet during the 1st quarter valued at $31,000. Bangor Savings Bank bought a new stake in Zimmer Biomet during the third quarter valued at $31,000. Family Firm Inc. bought a new position in Zimmer Biomet in the 2nd quarter worth about $33,000. J.Safra Asset Management Corp raised its holdings in shares of Zimmer Biomet by 712.1% in the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 235 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in shares of Zimmer Biomet during the second quarter worth about $43,000. Institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ZBH shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, September 17th. JPMorgan Chase & Co. dropped their price objective on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a report on Monday, September 16th. UBS Group cut their target price on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a research report on Thursday, August 8th. Evercore ISI dropped their price target on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Finally, Robert W. Baird reduced their price objective on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $123.94.

Zimmer Biomet Trading Up 0.7 %

ZBH traded up $0.77 during trading on Tuesday, hitting $104.37. 351,080 shares of the stock traded hands, compared to its average volume of 1,469,412. The firm has a market capitalization of $21.47 billion, a P/E ratio of 22.42, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 0.63. The firm has a 50-day moving average of $107.45 and a 200 day moving average of $111.19.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The company had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.94 billion. During the same period in the prior year, the business posted $1.82 earnings per share. Zimmer Biomet’s revenue for the quarter was up 3.9% on a year-over-year basis. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.97 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s dividend payout ratio is presently 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.